[The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
Our results suggest that the growth of tumors was significantly suppressed when the high-dose rIL-2 (2 x 10(4)U/day) was injected i.p. in mice bearing subcutaneously (s. c.) transplanted tumors. The inhibition effect on the growth of mouse hepatoma HAC was more potent than that on S180 group. It was found that rIL-2 increased significantly the survival of BALB/C mice bearing HAC tumor (P < 0.001). We have also shown that the adoptive transfer of unfractionated LAK cells plus rIL-2 was more effective than rIL-2 alone. The results also indicated that adherent LAK cells (A-LAK) in combination with rIL-2 had higher antitumor effects as compared to standard LAK cells plus rIL-2.
Wang
C
C
Shanghai Institute of Immunology, Shanghai Second Medical University.
Chai
L
L
Zhu
G
G
D000818:Animals; D005260:Female; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000627:therapeutic use; D012510:Sarcoma 180 / Q000628:therapy*
D007376:Interleukin-2; D011994:Recombinant Proteins